Aortic valve leaflets replacement

Aortic valve leaflets replacement refers to a medical or surgical procedure rather than a discrete biological molecule or receptor. The aortic valve contains leaflets (flaps) that open and close to control blood flow from the left ventricle to the aorta. When these leaflets become damaged (due to aortic stenosis, regurgitation, congenital defects or degeneration), they can be repaired, but often are surgically replaced with either mechanical or biological (tissue) valves. The procedure can be performed as open-heart surgery (Surgical Aortic Valve Replacement, SAVR), through minimally invasive approaches, or via catheter-based techniques (Transcatheter Aortic Valve Replacement, TAVR)[1][3][6][7]. This is a surgical intervention, not a pharmacological or molecular target. There are no drugs designed to bind to or modulate "aortic valve leaflets" directly as a molecular entity, nor are there molecular classifications or biomarker panels relevant to a receptor or enzyme. If you require information about a specific molecular or pharmacological target implicated in aortic valve pathology (e.g., a receptor involved in calcification or degeneration), please provide a more specific name or molecular entity.

Other names

Aortic valve replacementTranscatheter aortic valve replacement (TAVR)Surgical aortic valve replacement (SAVR)Aortic valve repair